Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer

Seminars in Nuclear Medicine

Volumn 40, Issue 2, 2010, Pages 145-152

  Middendorp, Marcus ^a   Grünwald, Frank ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CARBOPLATIN; CELECOXIB; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GEFITINIB; INTERLEUKIN 12; INTERLEUKIN 2; IODINE; ISOTRETINOIN; LITHIUM; MOTESANIB; OCTREOTIDE; PROTEIN P53; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; ROSIGLITAZONE; SODIUM IODIDE SYMPORTER; SOMATOSTATIN DERIVATIVE; SORAFENIB; THYROGLOBULIN; THYROTROPIN;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DIFFERENTIATED THYROID CARCINOMA; DRUG INDICATION; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PAPILLARY CARCINOMA; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROID CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT INDICATION; TREATMENT PLANNING;

ANIMALS; CELL DIFFERENTIATION; GENE THERAPY; HUMANS; IODINE RADIOISOTOPES; THYROID NEOPLASMS; THYROTROPIN;

EID: 74849086886     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.10.006     Document Type: Review

References (83)

1. Stokkel M.P., Duchateau C.S., and Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q J Nucl Med Mol Imaging 50 (2006) 78-87
2. Mallick U.K., and Charalambous H. Current issues in the management of differentiated thyroid cancer. Nucl Med Commun 25 (2004) 873-881
3. Biersack H.J., and Grünwald F. Thyroid Cancer. (ed 2) (2005), Springer, New York
4. Sclabas G.M., Staerkel G.A., Shapiro S.E., et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 186 (2003) 702-709
5. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
6. Passler C., Scheuba C., Asari R., et al. Importance of tumour size in papillary and follicular thyroid cancer. Br J Surg 92 (2005) 184-189
7. Shaha A. Selective surgical management of well-differentiated thyroid cancer. Ann NY Acad Sci 1138 (2008) 58-64
8. Bilimoria K.Y., Bentrem D.J., Ko C.Y., et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246 (2007) 375-381
9. Pazaitou-Panayiotou K., Capezzone M., and Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 17 (2007) 1085-1092
10. Sakorafas G.H., Giotakis J., and Stafyla V. Papillary thyroid microcarcinoma: A surgical perspective. Cancer Treat Rev 31 (2005) 423-438
11. Hay I.D., Hutchinson M.E., Gonzalez-Losada T., et al. Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period. Surgery 144 (2008) 980-987
12. D'Avanzo A., Treseler P., Ituarte P.H., et al. Follicular thyroid carcinoma: Histology and prognosis. Cancer 100 (2004) 1123-1129
13. Delbridge L., Parkyn R., Philips J., et al. Minimally invasive follicular thyroid carcinoma: Completion thyroidectomy or not?. ANZ J Surg 72 (2002) 844-845
14. Brennan M.D., Bergstralh E.J., van Heerden J.A., et al. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 66 (1991) 11-22
15. Furlan J.C., Bedard Y.C., and Rosen I.B. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg 198 (2004) 341-348
16. Demidchik Y.E., Demidchik E.P., Reiners C., et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 243 (2006) 525-532
17. Thompson G.B., and Hay I.D. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 28 (2004) 1187-1198
18. Gingalewski C.A., and Newman K.D. Seminars: Controversies in the management of pediatric thyroid malignancy. J Surg Oncol 94 (2006) 748-752
19. Carling T., Ocal I.T., and Udelsman R. Special variants of differentiated thyroid cancer: Does it alter the extent of surgery versus well-differentiated thyroid cancer?. World J Surg 31 (2007) 916-923
20. Dralle H., and Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab 22 (2008) 971-987
21. Ito Y., Jikuzono T., Higashiyama T., et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg 30 (2006) 1821-1828
22. Vorländer C., Lienenlüke R.H., and Wahl R.A. Lymph node dissection in papillary and follicular thyroid cancer. Chirurg 79 (2008) 564-570
23. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787-803
24. Luster M., Clarke S.E., Dietlein M., et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35 (2008) 1941-1959
25. Sawka A.M., Thephamongkhol K., Brouwers M., et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89 (2004) 3668-3676
26. Hay I.D., Grant C.S., Bergstralh E.J., et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?. Surgery 124 (1998) 958-964
27. Hay I.D., McConahey W.M., and Goellner J.R. Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113 (2002) 241-260
28. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94 (2006) 692-700
29. Mazzaferri E.L. A randomized trial of remnant ablation-In search of an impossible dream?. J Clin Endocrinol Metab 89 (2004) 3662-3664
30. Sawka A.M., Rotstein L., Brierley J.D., et al. Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. Thyroid 17 (2007) 1235-1242
31. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 92 (2007) 28-38
32. Jarzab B., Handkiewicz-Junak D., Wloch J., et al. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: A qualitative review. Endocr Relat Cancer 12 (2005) 773-803
33. Maxon III H.R., Englaro E.E., Thomas S.R., et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-A quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 33 (1992) 1132-1136
34. Lassmann M., Hänscheid H., Chiesa C., et al. EANM Dosimetry Committee: Series on standard operational procedures for pre-therapeutic dosimetry I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35 (2008) 1405-1412
35. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 2892-2899
36. Menzel C., Grünwald F., Schomburg A., et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 37 (1996) 1496-1503
37. Bernier M.O., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86 (2001) 1568-1573
38. Muresan M.M., Olivier P., Leclère J., et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 15 (2008) 37-49
39. McWilliams R.R., Giannini C., Hay I.D., et al. Management of brain metastases from thyroid carcinoma: A study of 16 pathologically confirmed cases over 25 years. Cancer 98 (2003) 356-362
40. Menzel C., Zaplatnikov K., Diehl M., et al. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun 25 (2004) 239-243
41. Kulkarni K., Van Nostrand D., Atkins F., et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16 (2006) 1019-1023
42. Koong S.S., Reynolds J.C., Movius E.G., et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84 (1999) 912-916
43. Sugino K., Ito K., and Takami H. Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH. Endocr J 53 (2006) 723-728
44. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 91 (2006) 926-932
45. Hänscheid H., Lassmann M., Luster M., et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47 (2006) 648-654
46. Duntas L.H., and Cooper D.S. Review on the occasion of a decade of recombinant human TSH: Prospects and novel uses. Thyroid 18 (2008) 509-516
47. Intenzo C.M., Jabbour S., Dam H.Q., et al. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med 35 (2005) 257-265
48. Tuttle R.M., Brokhin M., Omry G., et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49 (2008) 764-770
49. Haugen B.R., Cooper D.S., Emerson C.H., et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid 18 (2008) 687-694
50. 131I administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92 (2007) 3542-3546
51. Risse J.H., Grünwald F., Bender H., et al. Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis. Thyroid 9 (1999) 1253-1256
52. Robbins R.J., Driedger A., and Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16 (2006) 1121-1130
53. Lee N., and Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer 13 (2006) 971-977
54. Schuck A., Biermann M., Schober O., et al. Strahlentherapie des Schilddrüsenkarzinoms. [German]. Onkologe 11 (2005) 87-92
55. Biermann M., Pixberg M.K., Schuck A., et al. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 42 (2003) 244-250
56. Schwartz D.L., Lobo M.J., Ang K.K., et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 74 (2009) 1083-1091
57. Biondi B., Filetti S., and Schlumberger M. Thyroid-hormone therapy and thyroid cancer: A reassessment. Nat Clin Pract Endocrinol Metab 1 (2005) 32-40
58. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: What are the targets?. J Clin Endocrinol Metab 93 (2008) 1167-1169
59. Cooper D.S., Specker B., Ho M., et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8 (1998) 737-744
60. Heemstra K.A., Hamdy N.A., Romijn J.A., et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 16 (2006) 583-591
61. Biondi B., and Cooper D.S. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29 (2008) 76-131
62. Tuttle R.M., Leboeuf R., and Shaha A.R. Medical management of thyroid cancer: A risk adapted approach. J Surg Oncol 97 (2008) 712-716
63. Santini F., Bottici V., Elisei R., et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 87 (2002) 4160-4165
64. Williams S.D., Birch R., and Einhorn L.H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70 (1986) 405-407
65. Raue F. Chemotherapy in thyroid cancer: Indications and results [German]. Onkologe 3 (1997) 55-58
66. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16 (1999) 34-41
67. Grünwald F., Menzel C., Bender H., et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39 (1998) 1903-1906
68. Simon D., Körber C., Krausch M., et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: Final results of a pilot study. Eur J Nucl Med Mol Imaging 29 (2002) 775-782
69. Courbon F., Zerdoud S., Bastie D., et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 16 (2006) 1025-1031
70. Zhang Y., Jia S., Liu Y., et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 28 (2007) 251-255
71. Tepmongkol S., Keelawat S., Honsawek S., et al. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: A correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 18 (2008) 697-704
72. DeLellis R.A. Pathology and genetics of thyroid carcinoma. J Surg Oncol 94 (2006) 662-669
73. Baudin E., and Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8 (2007) 148-156
74. Coelho S.M., Carvalho D.P., and Vaisman M. New perspectives on the treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 51 (2007) 612-624
75. Gupta-Abramson V., Troxel A.B., Nellore A., et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008) 4714-4719
76. Sherman S.I., Wirth L.J., Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359 (2008) 31-42
77. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26 (2008) 4708-4713
78. Pennell N.A., Daniels G.H., Haddad R.I., et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18 (2008) 317-323
79. Spitzweg C. Gene therapy in thyroid cancer. Horm Metab Res 41 (2009) 500-509
80. Kohlfuerst S., Igerc I., Gallowitsch H.J., et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid 16 (2006) 1113-1119
81. Teunissen J.J., Kwekkeboom D.J., and Krenning E.P. Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17 (2006) 19-25
82. Iten F., Muller B., Schindler C., et al. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: Long-term results of a phase 2 clinical trial. Cancer 115 (2009) 2052-2062
83. Mrozek E., Kloos R.T., Ringel M.D., et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 (2006) 2201-2204